China's Premier IVD Exhibition
March 21–23, 2026 — Xiamen International Expo Center, Xiamen, Fujian Province, China
Athens Bioscience attended the 23rd China International In Vitro Diagnostic Expo (CACLP) and the co-located China IVD Supply Chain Expo (CISCE) in Xiamen this March. Athens' CEO John Mitchell and Beijing-based Sales Representative Sara Zhou were on the ground to meet with IVD manufacturers, academic researchers, and regional distribution partners across what is widely recognized as the largest and most influential gathering of the global IVD community.
CACLP 2026 returned to South China for the first time in over a decade, bringing the event to Xiamen — a strategic gateway to the Guangdong, Fujian, and broader South China economic corridor. The 2025 edition set new records with more than 45,000 professional visitors and 1,350 exhibitors from 23 countries, and the 2026 edition was expected to surpass those milestones with an upgraded venue layout, integrated academic programming, and expanded international participation.
Why CACLP Matters for Athens
The Scale of China's IVD Market
China's IVD industry continues on one of the fastest growth trajectories in the global diagnostics landscape, driven by an aging population, expanding hospital infrastructure, and increasing demand for precision diagnostics at the primary care level. For upstream suppliers of native human proteins — the essential raw materials used in diagnostic assay development, calibration, and quality control — China represents a market of enormous and growing strategic importance.
Full Value Chain Visibility
CACLP and CISCE together offer something few events can match: end-to-end visibility across the entire IVD value chain, from upstream raw materials and key components to finished instruments, reagents, and clinical applications. For Athens Bioscience, this means direct engagement with both the manufacturers who incorporate our proteins into their diagnostic platforms and the supply chain partners who help deliver those materials into one of the world's fastest-moving markets.
Athens' Objectives in Xiamen
Deepening Existing Relationships
Athens has built meaningful commercial momentum in China over the past year, with regional distributor sales growing rapidly since the program launched in mid-2025. CACLP provides a critical opportunity to meet face-to-face with established partners, review market strategy, and align on product placement priorities for the year ahead.
Expanding IVD Manufacturer Engagement
With growing international demand for Athens' high-purity native proteins — particularly among IVD companies developing calibrators, controls, and immunoassay platforms — the team engaged directly with Chinese diagnostic manufacturers evaluating new raw material suppliers. Athens' differentiated capabilities in protein purity verification, including LC-MS/MS compositional analysis and rigorous lot-to-lot consistency, are directly relevant to the quality requirements of this market.
Academic and Research Community
CACLP's concurrent academic programming, including the 11th China Experimental Medicine Conference (CEMC) and the 13th China IVD Industry Development Conference (CIIDC), provided insight into emerging diagnostic trends and research applications. Athens' proteins are widely cited in peer-reviewed publications and used in academic research institutions globally — connections made at CACLP can open new channels for collaborative research and product development.
On-the-Ground Presence
"Being in Xiamen with Sara — who works with our Chinese partners every day — allows us to combine strategic vision with local market intelligence. Our customers and partners in China deserve the same level of direct engagement we bring to every market we serve. CACLP is the place to make that happen."
— John Mitchell, CEO, Athens Bioscience
Athens Bioscience's participation in CACLP and CISCE reflects the company's expanding commitment to the Asia-Pacific region and its belief that the strongest commercial relationships are built through direct, technical, face-to-face engagement — no matter the distance.